SSShreyas Shirodkar

Shreyas Shirodkar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shreyas Shirodkar has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Aaron Cumpston

    Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, WV

    1 shared publication
  • Abraham S. Kanate

    Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, WV

    1 shared publication
  • Amir Kamran

    Hematology/Oncology Department, Charleston Area Medical Center, Charleston, USA

    1 shared publication
  • Carl Shultz

    Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, WV

    1 shared publication
  • Chelby Wakefield

    Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, WV

    1 shared publication
  • Jennifer Collins

    Center for Health Services and Outcomes Research, Charleston Area Medical Center, Charleston, USA

    1 shared publication

Latest Publications

  • Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study

    by Carl Shultz, Shreyas Shirodkar, Chelby Wakefield, Steven Rollins, Sijin Wen, Kelly Ross, Michael Craig, Aaron Cumpston, Mehdi Hamadani, Abraham S. Kanate, et al.

  • The impact of neutropenia severity in the setting of recent chemotherapy on mortality in sepsis

    by Shreyas Shirodkar, Saad Javaid, Jennifer Collins, Khawaja Omar, Amir Kamran

    Background Sepsis and septic shock are major causes of non-relapse mortality in cancer patients, with chemotherapy-induced neutropenia increasing infection risk. The prognostic impact of neutropenia remains unclear across cancer subtypes. Patients and methods We conducted a retrospective cohort study using the TriNetX Research Network, comprising deidentified data from over 141 million patients across 105 U.S. health care organizations. Adults with select solid cancers who received chemotherapy and developed severe sepsis with septic shock from 2013 to 2024 were included. Patients were stratified by neutropenia severity (< 0.5 × 103/µL vs. 0.5–1.5 × 103/µL), and propensity score matching was applied to balance demographics, comorbidities, and treatment variables. Outcomes including short- and long-term mortality, organ failure, bacteremia, and immune-related adverse events were assessed using Kaplan–Meier survival analysis. Results Among 1083 eligible patients (184 severe, 899 mild–moderate neutropenia), severe neutropenia was associated with significantly worse survival at all timepoints, with median survival of 13 days versus 106 days and hazard ratios of 1.56–2.03 from 30 days to 1 year (all p < 0.001). Secondary outcomes showed no difference in immune-related adverse events, a nonsignificant trend toward increased organ failure, and higher rates of bacteremia in the severe neutropenia cohort. Conclusions Greater severity of chemotherapy-associated neutropenia is linked to worse short-term survival and increased complications in cancer patients with septic shock. Stratifying by neutrophil count bands revealed that severe neutropenia (< 0.5 × 103/µL) independently predicts poorer outcomes, emphasizing its value for risk stratification and guiding clinical management.